Company overview

Harrow, Inc. supplies medicines that eye-care professionals use to treat eye conditions and care for patients undergoing eye procedures, primarily in the United States. Its FDA-approved branded products generate most of its revenue, with IHEEZO and VEVYE together accounting for the majority of company sales. Wholesalers buy the products and distribute them to pharmacies and healthcare providers; most U.S. branded sales pass through McKesson, Cencora, Western Wellness and Cardinal Health.

That business depends on doctors prescribing or using the medicines and on private insurance, Medicare and Medicaid covering treatment. Payors’ coverage decisions, discounts and rebates affect how much Harrow earns. Harrow does not manufacture its branded medicines, so it also depends on outside manufacturers for supply.

Its second business, ImprimisRx, makes customized eye medicines when commercially available products may not meet a patient’s needs, such as different strengths or preservative-free formulations. Its New Jersey facilities fill patient-specific prescriptions or supply medicines for use in medical offices, and the pharmacy business is primarily cash-pay. These compounded formulations are not FDA-approved. Federal and state rules restrict what it can make and where it can sell; surrendering its California pharmacy and outsourcing-facility licenses in February 2026 restricted sales of certain compounded products in that state.